Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - 21 CFR Part 1271
          - [Docket No.  97N-484R]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Interim final rule; correction

# SUMMARY:

                        The Food and Drug Administration (FDA) is correcting an interim final rule that published in the                         **Federal Register**                         on January 27, 2004 (69 FR 3823).  The interim final rule excepted human dura mater and human heart valve allografts, currently subject to application or notification requirements under the Federal Food, Drug, and Cosmetic Act from the scope of the definition of “human cells, tissues, or cellular or tissue-based products (HCT/P's)” subject to the registration and listing requirements contained in 21 CFR Part 1271.  That definition became effective on January 21, 2004.  The interim final rule published with some errors.  This document corrects those errors.                    

# FOR FURTHER INFORMATION CONTACT:

Paula S. McKeever, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD  20852-1448, 301-827-6210.

# SUPPLEMENTARY INFORMATION:

                    In the FR Doc. 04-1733, appearing on page 3824 in the                     **Federal Register**                     of Tuesday, January 27, 2004, the following corrections are made:                

                    1.  On page 3824, in the                     **DATES**                     section, by removing the sentence “The compliance date is March 29, 2004.”                

                    2.  On page 3824, under                     **SUPPLEMENTARY INFORMATION**                     in the I.  Background section, the phrase “FDA understands that many establishments may have reasonably expected FDA to delay the effective date of this provision again, since the donor suitability and GTP rules are not yet finalized” is revised to read:                

“FDA understands that many establishments may have reasonably expected FDA to delay the effective date of this provision again, since the donor suitability and GTP rules are not yet finalized.  Accordingly, FDA expects that affected firms will be in compliance with these requirements by March 29, 2004, and not on January 21, 2004, the effective date of the definition regulation.”

Dated: January 29, 2004.

William K. Hubbard,

Associate Commissioner for Policy and Planning.

[FR Doc. 04-2312 Filed 1-30-04; 3:49 pm]

BILLING CODE 4160-01-S